Mirxes Holding Company Limited released a quarterly progress report on its trading resumption efforts, detailed the postponement of its 2026 annual general meeting and confirmed the continued suspension of its shares on the Hong Kong Stock Exchange.
Key developments are as follows:
• Independent investigation: An Investigation supervised by an Independent Investigation Committee is ongoing to address outstanding audit matters relating to prepayments and significant cash outflows after 31 December 2025. The committee is aligning the scope of work with the Hong Kong Stock Exchange’s resumption conditions and will announce findings when available.
• Management integrity: To date, the board reports no issues concerning the integrity, competence or character of senior management or any parties with substantial influence over the Group’s operations.
• Internal control review: The board has engaged an independent external adviser to conduct an internal control review that initially covers procurement and treasury functions. The scope may widen depending on investigation results.
• Outstanding financial statements: Mirxes is working with auditors to finalise and publish its FY 2025 annual results and dispatch the corresponding annual report.
• Listing Rule compliance: Management states that day-to-day research, development, manufacturing and commercialisation of molecular diagnostic tests continue “as usual” and that prepayments and cash outflows should not materially affect operations or asset levels required under Rule 13.24.
• Market disclosure: The company pledges to continue issuing timely announcements to keep shareholders and investors informed of all material information.
• AGM delay: Because FY 2025 results and the annual report are not yet available, the annual general meeting—originally required by 30 June 2026—will be postponed. A new date will be announced in due course.
• Trading status: Mirxes shares have been suspended since 09:00 on 1 April 2026 and will remain so until all resumption conditions set by the Stock Exchange are satisfied.
The company’s board will release further updates on the investigation, internal control findings, publication of FY 2025 financials and the resumption timetable when material progress is achieved.